Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 3Phase 4 2Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 2Breast 1

Conditions

Uterine Cervical Neoplasms 2Condylomata Acuminata 2Vomiting 1Nausea 1Breast Neoplasms 1

Interventions

Cisplatin 726Carboplatin 609Paclitaxel 579Cyclophosphamide 516Radiotherapy 511Docetaxel 477Fluorouracil 454Gemcitabine 438Doxorubicin 383Capecitabine 362Dexamethasone 328Oxaliplatin 289pembrolizumab 283Leucovorin 283Bevacizumab 275Etoposide 272Vincristine 270Rituximab 246Prednisone 223Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 176Irinotecan 174Methotrexate 171Lenalidomide 137Nivolumab 136Filgrastim 135Epirubicin 129Tamoxifen 128

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Duration of Therapy × Clear all
NCT00092196 2017-05-05

Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 3 Completed
820 enrolled
Breast

Breast Neoplasms, Nausea, Vomiting

NCT00092482 2017-03-22

Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 3 Completed
3,882 enrolled
Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT00517309 2017-03-22

FUTURE

Merck Sharp & Dohme LLC

Phase 3 Completed
1,877 enrolled
Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata

Data powered by HemOnc (CC BY 4.0) Colophon âš¡